Print this Article
RSSBackchannelmedia
- Secure Balance(TM) Infomercial Expected to Reach Millions of Consumers -
CALIMESA, Calif., Aug. 30 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. , a medical device manufacturer of OxyAlert(TM), OxyView(TM), and Secure Balance(TM), and also a developer of Pure Produce(TM), announces that it has completed the Secure Balance(TM) infomercial and expects positive results.
While the Company launches a national advertising and marketing campaign, the release of the Secure Balance(TM) infomercial will directly reach thousands of physicians and millions of consumers. "The 10 minute infomercial on the Secure Balance(TM) products and services was strategically designed to penetrate competitive products and reach neurology and chiropractic markets." Said Jacob Green, MD, President of the Southeastern Neuroscience Institute in Jacksonville, Florida.
The Company has contracts with major neurology and chiropractic based advertising agencies to publish Secure Balance(TM) layouts within their core journals. Further, the Secure Balance(TM) products will appear at the 58th Annual Meeting for the American Academy of Neurology in April-2006, and more recently the Secure Balance(TM) products were invited to be debuted at the International Academy of Chiropractic Neurology (IACN) Annual Symposium on Palmer's Campus in Daytona Beach, FL on October 13-16, 2005. "We would like to invite your company to send a representative to address our group for 15-30 minutes, followed by Q&A by our panel of experts. You are also invited to set up an exhibitors booth if you so desire." Said Dr. Ferezy, DC, FIACN and President of IACN.
"Our Secure Balance(TM) infomercial is easily accessible from the Company website, and will spread like wild fire among the medical industry. We expect an increase in Secure Balance(TM) sales and this will certainly feed our growth when we are listed on the OTCBB." Said Scott Sand, CEO & Chairman of Ingen Technologies, Inc..
The Company auditors have completed the 2003-2004 financial audits, and have stated to complete 2004-2005 audits within the next several days. "The complexity of the audits resulted in taking longer to complete. The 2003-2004 year involved the auditing of all stock holders, merger agreements and CRTZ financial data. With that behind us we will finish 2004-2005 by next week, and begin on the first quarter of 2005-2006 year ending May 31, 2006." Said Harold Spector,CPA and principal of Spector & Wong LLP.
The year ending May 31, 2004 shows a Net Operating Loss (NOL Carry Forward) of $5,307,034.62 due to expenses invested into Research & Development (R & D) of the Company product lines. Total sales for 2003-2004 were $901,542, with expenses of $689,039.62. Net(income) Before Taxes was $278,530.42.
About Ingen Technologies, Inc.
Ingen Technologies, Inc. is a public company trading under NASDAQ OTC: IGTN, which has been in business since 1999. IGTN is a medical device manufacturer and a growth-oriented company that owns US patent(s), trademarks, and proprietary medical products.
The Company's flagship product is OxyAlert(TM), a second-generation design of the Company's BAFI(TM) product line. Both of these products have been issued two US Patents: Patent No. 6,137,417 issued on October 24, 2000 and Patent No. 6,326,896 issued on December 4, 2001. Both of these products are low-oxygen safety warning devices used on remote oxygen cylinders for patients, commercial aircraft, military transport, and fire and safety equipment. OxyAlert(TM) technology encompasses the use of digital sensing and RF frequency transfer so that care givers can access a hand-held remote to monitor the actual oxygen level of any oxygen cylinder at a reasonable distance.
The newest product, OxyView(TM), has a patent pending, and is a pneumatic gauge that provides visual safety warning of oxygen flow to hospitalized patients. This product enhances the safety, assurance and accuracy of hospitalized patients being administered oxygen from any source. OxyView(TM) is a lightweight pneumatic gauge that is attached to the oxygen tubing just below the neck. It informs the nursing staff of oxygen flow rate near the patient. It could quickly inform the hospital staff of any leak or inaccuracy between the delivery source and the patient.
The Secure Balance(TM) product is a private-label product that includes a vestibular function testing system and balance therapy system. The vestibular function testing system is manufactured by Interacoustics LTD. in Denmark and is referred to as the VNG. The balance therapy system is manufactured by SportKAT(R), Inc. in San Diego, California. The Secure Balance(TM) program provides equipment, education and training about balance and fall prevention to physicians and clinicians worldwide.
The Pure Produce(TM) product is a continuing research & development program currently under design. This program uses hydroponics technology to grow various plants without the use of soil, fertilizer and water consumption. The Company anticipates entering the nutriceutical and pharmaceutical markets over the next two years.
"Our team of professionals has developed our medical products for the ever-increasing elderly population. Our products are superior to any of our competition and they allow for effective medical product availability to seniors, and at the same time the increasing senior population allows for a steady growth in sales and profits," said Scott Sand, CEO & Chairman of Ingen Technologies.
For more information, visit www.ingen-tech.com
Investor Relations Contact: Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc.
285 E. County Line Road
Calimesa, CA 92320
800-259-9622
951-675-3266
800-777-1186 FAX
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements that are made pursuant to "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Source: Ingen Technologies, Inc.
CONTACT: Scott R. Sand, C.E.O & Chairman of Ingen Technologies, Inc., +1-800-259-9622, or +1-951-675-3266, or fax, +1-800-777-1186, scottsand@ingen-tech.com
Web site: http://www.ingen-tech.com/
